Anavex went out of their way today to update n from 100 to 120, a day after updating the n=100 OLE trial on October 5th. If accurate, what does an n=120 OLE extension trial tell us about potential efficiacy in an n=120 PDD trial that has completed?
OLE 100% participation as of October 6th and consistent with the 100% OLE rollover rate Missling decalred a few months ago.
This is unbelievably good; unprecedented if you ask me.
Again, if accurate, this isnt "connecting dots" or just "another data point.
100% OLE rollover rate and SIUF paying for 50% of the next Anavex Parkinsons trial.
This is generational wealth stuff for those that want to pay attention.